Measurement of health-related quality of life during chemotherapy – the importance of timing

Kristensen, Are Korsnes; Solheim, Tora Skeidsvoll; Amundsen, Tore; Hjelde, Harald; Kaasa, Stein; Sørhaug, Sveinung; Grønberg, Bjørn Henning

doi:10.1080/0284186x.2017.1279748

Cited by 16 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is important to examine changes in outcomes (multiple symptoms, symptom dimensions, and QoL) over time from the time of pretreatment throughout the chemotherapy treatment. Such changes have been shown to be important in previous studies of patients with lung cancer [72] and diverse cancer diagnoses [71]; however, they have been studied less in CRC patients. [47] The timing of the assessment points during the chemotherapy cycle is important because various side effects of chemotherapy can occur at different times, [72] and be present for a shorter time period, which means that there is a risk of missing some by infrequent assessments during the course of chemotherapy or only on the day of chemotherapy.…”

Section: Methodsmentioning

confidence: 99%

“…Such changes have been shown to be important in previous studies of patients with lung cancer [72] and diverse cancer diagnoses [71]; however, they have been studied less in CRC patients. [47] The timing of the assessment points during the chemotherapy cycle is important because various side effects of chemotherapy can occur at different times, [72] and be present for a shorter time period, which means that there is a risk of missing some by infrequent assessments during the course of chemotherapy or only on the day of chemotherapy. [71,72] Assessments after 3 and 7 days provided information about the most acute side effects of chemotherapy, through the chemotherapy cycle, in this cohort.…”

Section: Methodsmentioning

confidence: 99%

“…[47] The timing of the assessment points during the chemotherapy cycle is important because various side effects of chemotherapy can occur at different times, [72] and be present for a shorter time period, which means that there is a risk of missing some by infrequent assessments during the course of chemotherapy or only on the day of chemotherapy. [71,72] Assessments after 3 and 7 days provided information about the most acute side effects of chemotherapy, through the chemotherapy cycle, in this cohort. These changes in symptoms may be missed when assessments are conducted only on the day of next chemotherapy administration.…”

Section: Methodsmentioning

confidence: 99%

“…The use of patients self-reported symptoms is important to understanding the complex symptoms experienced by CRC patients throughout the daily chemotherapy trajectory. [72] The term patient-reported outcome measures (PROMs) refers to "any report coming directly from patients about a health condition and its treatment" using self-reported instruments or questionnaires. [73] PROMs are essential in clinical patient decision-making, research, and political health decisions.…”

Section: Self-reported Symptomsmentioning

confidence: 99%

See 3 more Smart Citations

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

Röhrl

Guren

Astrup

et al. 2020

European Journal of Oncology Nursing

View full text Add to dashboard Cite

, that funded the PhD program. My deep gratitude also goes to the Norwegian Nursing Society for additional grants. First of all, I wish to dedicate this thesis to the patients and their families who gave me the privilege of sharing their experiences during one of the toughest journey of their life. I express my deepest gratitude to my main supervisor and principal investigator of the "Cluster study", Tone Rustøen! Thank you for believing in me, for your excellent supervision, and giving me the opportunity to introduce me to science! I admire your positivism, knowledge and enthusiasm! These years have truly changed me as a professional nurse and as a person! Grate thankfulness goes to my co-supervisor Marianne Grønlie Guren for exemplary supervision! For being the most knowledgeable positive doctor I have worked with. You are a true role model! Thank you for introducing me into the world of gastroenterology!

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Self-reported Symptomsmentioning

confidence: 99%

See 2 more Smart Citations

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

Röhrl

Guren

Astrup

et al. 2020

European Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…6 Symptom prevalence has been described mostly in patients receiving intravenous chemotherapy or patients with breast cancer on adjuvant endocrine therapy. 8,9 Because patients on oral therapy do not receive the same degree of oversight and monitoring as those on intravenous treatment, 10,11 which could negatively influence adherence, 12 it is important to understand patients' symptom burden, adherence, and distress in a clinical setting.…”

Section: Introductionmentioning

confidence: 99%

Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life

Jacobs

Ream

Pensak

et al. 2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: Oral therapies are increasingly common in oncology care. However, data are lacking regarding the physical and psychologic symptoms patients experience, or how these factors relate to medication adherence and quality of life (QoL). Materials and Methods: From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center. Patients completed baseline assessments of adherence with electronic pill cap, QoL, symptom severity, mood, social support, fatigue, and satisfaction with clinicians and treatment. Relationships among these factors were examined using Pearson product-moment correlations and multivariable linear regression. Results: At baseline, the mean electronic pill cap adherence rate showed that patients took 85.57% of their oral therapy. The most commonly reported cancerrelated symptoms were fatigue (88.60%), drowsiness (76.50%), disturbed sleep (68.20%), memory problems (63.10%), and emotional distress (60.80%). Patients who reported greater cancer-related symptom severity had lower adherence (r5 20.20). In a multivariable regression, greater depressive and anxiety symptoms, worse fatigue, less social support, lower satisfaction with clinicians and treatment, and higher symptom burden were associated with worse QoL (F [10, 146]550.53; adjusted R 2 50.77). Anxiety symptoms were most strongly associated with clinically meaningful decrements in QoL (b5 27.10; SE50.22). Conclusions: Patients prescribed oral therapies struggle with adherence, and cancer-related symptom burden is high and related to worse adherence and QoL. Given perceptions that oral therapies are less impairing, these data underscore the strong need to address adherence issues, symptom burden, and QoL for these patients.

show abstract

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

Davies

Trask²,

Demeter

et al. 2020

Ann Hematol

View full text Add to dashboard Cite

Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. Patients were randomized 1:1 to receive induction therapy with obinutuzumab- or rituximab-chemotherapy and maintenance in responders. Health-related quality of life was assessed using the Functional Assessment of Cancer Treatment-Lymphoma questionnaire, incorporating well-being and lymphoma-specific subscales. Assessments were performed at baseline, and during induction, maintenance, and follow-up (maximum 84 months). Clinically meaningful responses were defined by minimally important difference values. Of 1202 randomized patients (median follow-up 57.4 months), 557/601 (92.7%; obinutuzumab-chemotherapy) and 548/601 (91.2%; rituximab-chemotherapy) completed all Functional Assessment of Cancer Treatment-Lymphoma scales at baseline. Mean baseline health-related quality of life scores were similar between both arms, with all patients having some functional impairment and lymphoma symptoms. Over the course of treatment, mean health-related quality of life remained similar in both arms. Equal proportions of patients in both arms achieved minimally important difference by the Functional Assessment of Cancer Treatment-Lymphoma lymphoma-specific subscale and summary scales throughout induction, maintenance, and follow-up. On each summary scale, ~ 50% of patients in each arm achieved minimally important difference by maintenance month 2. In GALLIUM, similar improvements in health-related quality of life were seen with obinutuzumab- and rituximab-chemotherapy, suggesting that both treatments reduced lymphoma-related symptoms, and treatment-related side effects did not abrogate these improvements in well-being. ClinicalTrials.gov identifier: NCT01332968. Electronic supplementary material The online version of this article (10.1007/s00277-020-04021-6) contains supplementary material, which is available to authorized users.

show abstract

Measurement of health-related quality of life during chemotherapy – the importance of timing

Abstract: There was a clinically relevant variation of HRQoL during chemotherapy cycles, with increased symptom burden the first week following treatment. Our results suggest that timing of HRQoL assessment can influence the chances of detecting differences between the treatment regimens.

Cited by 16 publications

References 22 publications

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

Contact Info

Product

Resources

About